FDA Clearance Tracker · P160048-S026
Eversense E3 Continuous Glucose Monitoring System (CGM System) - Entire System, Eversense E3 Sensor, Eversense E3 Insert
Last checked: Nov 20, 2026Latest source record: Dec 5, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Dec 5, 2023
Approved
Time to decision
116 days
Received Aug 11, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P160048-S026
- Device name
- Eversense E3 Continuous Glucose Monitoring System (CGM System) - Entire System, Eversense E3 Sensor, Eversense E3 Insert
- Applicant
- Senseonics, Incorporated
- Applicant location
- Germantown, MD
- Received
- Aug 11, 2023
- Decided
- Dec 5, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P160048
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for a manufacturing site located at RR Donnelley - Supply Chain Solutions, 1600 Disk Dr., Plover, WI 54467-3131, to perform kitting of the final components, labeling, storage, and distribution of the Eversense E3 CGM System.
Source documents
Other decisions for Senseonics, Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241335 · Decided Sep 16, 2024 · 126 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.